Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial.
Lavezzi SM, de Jong J, Neyens M, Cramer P, Demirkan F, Fraser G, Bartlett N, Dilhuydy MS, Loscertales J, Avigdor A, Rule S, Samoilova O, Goy A, Ganguly S, Salman M, Howes A, Mahler M, De Nicolao G, Poggesi I.
Lavezzi SM, et al.
Pharm Res. 2019 May 1;36(7):93. doi: 10.1007/s11095-019-2605-8.
Pharm Res. 2019.
PMID: 31044267
Clinical Trial.